Back to results
US 2023/0271986 A1Published application
Crystalline or Amorphous form of Bcl-2/Bcl-xL inhibitor compound or its salts
AssigneesAscentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group Corp Limited
InventorsJianfeng WEN, Yanqiong LIN, Jianpeng FENG, Zhenzhong SHAO, Huirong LU, Weidong LI
Life of this patent
Estimating the term…
Abstract
Disclosed herein are a crystalline or amorphous form of a Bcl-2/Bcl-xL inhibitor compound or a salt thereof, and a preparation method and application thereof.
Claims30
A crystalline or amorphous form of the compound of formula 1 or its salt:
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
19-25. (canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.